googlemarker

CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & Drugs MCap (Rs. in Mn) : 478401.81 Face Value (Rs.) : 2 House : Cipla
BSE594.20-5.8 (-0.97 %)
PREV CLOSE (Rs.) 600.00
OPEN PRICE (Rs.) 598.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 594.20 (121)
VOLUME 36453
TODAY'S LOW / HIGH (Rs.)587.00 598.40
52 WK LOW / HIGH (Rs.)479 663
NSE593.05-8.85 (-1.47 %)
PREV CLOSE( Rs. ) 601.90
OPEN PRICE (Rs.) 600.50
BID PRICE (QTY) 593.05 (863)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1125208
TODAY'S LOW / HIGH(Rs.) 586.20 600.50
52 WK LOW / HIGH (Rs.)480.2 663.4
1D 1M 3M 1Y 3Y 5Y
Trade Value (Rs. in Lacs)
216.00
Dividend Yield(%)
0.34
TTM EPS (Rs.)
15.77
P/E Ratio
37.68
Book Value (Rs.)
172.31
Face Value (Rs.)
2
MCap (Rs. in Mn)
478401.81
Price/Earning (TTM)
26.71
Price/Sales (TTM)
4.32
Price/Book (MRQ)
3.45
PAT Margin (%)
8.88
ROCE (%)
9.34
Incorporation Year : 17-08 1935

Management Info :

Y K Hamied - Chairman Umang Vohra - Managing Director

Registered Office :

Address : Cipla House,Peninsula Business Park,Ganpatrao Kadam Marg, Lower Parel,
Mumbai,
Maharashtra-400013

Phone : 022-24826000 / 022-24826951

Website : www.cipla.com

Registrars Details :

Karvy Computershare Pvt Ltd
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg, MCX
17Apr USFDA conducts cGMP audit at Cipla’s I
The US Food and Drug Administration (USFDA) has conducted a routine curr..
16Apr Tata Steel, BEML and Cipla to see some
Tata Steel achieved a 6.8% rise in production in FY18 to 12.48 million t..
16Apr Cipla’s arm recalls 11 lots of antidep
Cipla’s arm InvaGen Pharmaceuticals Inc is recalling 11 lots of antidepr..
QTR Dec 17 ANNUAL 17
Net Profit4185.49749.4
Gross Profit 5805.6 11869.4
Operating Profit 7203.4 17261.1
Net Sales 29699.5 109745.8
Rs. in Millions
Zandu Realty (BSE)
img  2099.45 (3.61%)
M.Cap (Rs. in Cr)165.99
Sanofi India (BSE)
img  4960.90 (0.55%)
M.Cap (Rs. in Cr)11653.49
Mercury Laboratories (BSE)
img  425.25 (5.00%)
M.Cap (Rs. in Cr)48.96
Gufic Biosciences (BSE)
img  132.90 (12.15%)
M.Cap (Rs. in Cr)953.73
PROMOTERS
37.21%
NON-INSTITUTION
24.69%
MUTUAL FUNDS/UTI
10.07%
FI/BANKS/INSURANCE
3.81%
FII
0.31%
GOVERNMENT
0%
Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day.....Issued in the interest of investors.  |  No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. |  KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
Dear Client, Pursuant to SEBI regulation, update your KYC details through KRA form with supporting documents at earliest to complete KYC-KRA requirement. If already submitted, kindly ignore. For any information, in this regard, please contact to our KYC Department on 022-66556772/73/74 or email at kyc@satco.co.in.
  • NSE - INZ 230012635 | 
  • BSE - INZ 010012839 | 
  • MCX - IN2000026431 / FMC : MCX/TCM/CORP/0598  | 
  • NCDEX - IN2000026431 / FMC : NCDEX/TM/CORP/1138 | 
  • CDSL – IN-DP-CDSL-727-2014  | 
  • PMS - INP000003492  | 
  • RESEARCH – INH000002343
  • © Copyright 2015. SATCO CAPITAL MARKETS LTD. || Designed Developed & Content Powered By Accord Fintech Pvt.Ltd.
VISIT COUNT     689833